eligible for benefits (see paragraph (b)(2)(iv) of this section).

(iii) The provisions of paragraph (b)(2)(i) apply to communications
between you and your non-attorney
representative only if the
communications would be subject to the
attorney-client privilege, if your non-
attorney representative were an
attorney. The provisions of paragraph
(b)(2)(ii) apply to the analysis of your
claim by your non-attorney
representative only if the analysis of
your claim would be subject to the
attorney work product doctrine, if your
non-attorney representative were an
attorney.

(iv) The attorney-client privilege
generally protects confidential
communications between an attorney
and his or her client that are related to
providing or obtaining legal advice. The
attorney work product doctrine
generally protects an attorney’s analysis,
theories, mental impressions, and notes.
In the context of your disability claim,
neither the attorney-client privilege nor
the attorney work product doctrine
allows you to withhold factual
information, medical source opinions,
or other medical evidence that we may
consider in determining whether or not
you are eligible for benefits. For
example, if you tell your representative
about the medical sources you have
seen, your representative cannot refuse
to disclose the identity of those medical
sources to us based on the attorney-
client privilege. As another example, if
your representative asks a medical
source to complete an opinion form
related to your impairment(s),
symptoms, or limitations, your
representative cannot withhold the
completed opinion form from us based
on the attorney work product doctrine.
The attorney work product doctrine
would not protect the source’s opinions
on the completed form, regardless of
whether or not your representative used
the form in his or her analysis of your
claim or made handwritten notes on the
face of the report.

(c) Your responsibility. You must
inform us about or submit all evidence
known to you that relates to whether or
not you are blind or disabled. When you
submit evidence received from another
source, you must submit that evidence
in its entirety, unless you previously
submitted the same evidence to us or we
instruct you otherwise. If we ask you,
you must inform us about:

(1) Your medical source(s);
(2) Your age;
(3) Your education and training;
(4) Your work experience;
(5) Your daily activities both before
and after the date you say that you
became disabled;
(6) Your efforts to work; and
(7) Any other factors showing how
your impairment(s) affects your ability
to work. In §§416.960 through
416.969a, we discuss in more detail the
evidence we need when we consider
vocational factors.

Subpart N—[Amended]

§ 416.1435 Submitting evidence prior to a
hearing before an administrative law judge.

You should submit information or
evidence as required by §416.912 or any
summary of the evidence to the
administrative law judge with the
request for hearing or within 10 days
after filing the request, if possible. Each
party shall make every effort to ensure
that the administrative law judge
receives all of the evidence (see
§416.912) or all of the evidence is
available at the time and place set for the
hearing.
PART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

Dated: March 16, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 73
[Docket No. FDA–2013–C–1008]
Listing of Color Additives Exempt From Certification; Synthetic Iron Oxide

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the color additive regulations to provide for the expanded safe use of synthetic iron oxide as a color additive to include use in soft and hard candy, mints, and chewing gum. This action is in response to a petition filed by Wm. Wrigley Jr. Company (Wrigley).

DATES: This rule is effective April 21, 2015. See section X for further information on the filing of objections. Submit either electronic or written objections and requests for a hearing by April 20, 2015.

ADDRESSES: You may submit either electronic or written objections and requests for a hearing, identified by Docket No. FDA–2013–C–1008, by any of the following methods:

Electronic Submissions
Submit electronic objections in the following way:
• Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.

Written Submissions
Submit written objections in the following ways:
• Mail/Hand delivery/Courier (for paper submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Instructions: All submissions received must include the Docket No. FDA–2013–C–1008 for this rulemaking. All submissions received will be posted without change to http://www.regulations.gov, including any personal information provided. For detailed instructions on submitting objections, see the “Objections” heading of the SUPPLEMENTARY INFORMATION section.

Docket: For access to the docket to read background documents or objections received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.


SUPPLEMENTARY INFORMATION:
1. The authority citation for 21 CFR part 14 continues to read as follows:

Authority: 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e), the Agency finds good cause to dispense with notice and public comment procedures and to proceed to an immediate effective date on this rule. Notice and public comment and a delayed effective date are unnecessary and are not in the public interest as this final rule merely removes the name of the Antiviral Drugs Advisory Committee from the list of standing advisory committees in § 14.100 (21 CFR 14.100).

Therefore, the Agency is amending § 14.100(c) as set forth in the regulatory text of this document.

List of Subjects in 21 CFR Part 14
Administrative practice and procedure, Advisory committees, Color additives, Drugs, Radiation protection.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 14 is amended as follows:

PART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

§ 14.100 [Amended]

1. The authority citation for 21 CFR part 14 continues to read as follows:


§ 14.100 [Amended]

2. Section 14.100 is amended by removing paragraph (c)(3) and redesignating paragraphs (c)(4) through (18) as paragraphs (c)(3) through (17).